Lipigan

Atorvastatin, the active ingredient in Lipigan, is an HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is used in adults to manage hypercholesterolemia, mixed dyslipidemia, and to reduce cardiovascular risk, including patients at risk of myocardial infarction and stroke.

GNH USA supplies Lipigan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Atorvastatin is a statin medication that acts on lipid metabolism to lower cholesterol. Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Mixed dyslipidemia: improves the overall lipid profile by lowering triglycerides and raising HDL‑cholesterol. Cardiovascular disease prevention: decreases the risk of myocardial infarction, stroke and related events in primary and secondary prevention settings.

Atorvastatin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache. - Myalgia: muscle aches without weakness. - Abdominal discomfort: nausea, dyspepsia or stomach pain. - Elevated liver enzymes: mild increase in ALT or AST. - Diarrhea: loose stools. - Fatigue: feeling of tiredness. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible kidney injury. - Hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Allergic reactions: rash, angioedema or anaphylaxis. - Memory loss: rare reversible cognitive impairment. - Severe liver injury: jaundice or hepatic failure. - Myopathy with weakness: significant muscle weakness accompanied by pain.

When prescribing Lipigan, several safety considerations are recommended. Pregnancy: contraindicated; teratogenic risk (Category X). Liver disease: avoid in active hepatic impairment. Renal impairment: dose may need adjustment in severe cases. Drug interactions: review concomitant medications for CYP3A4 substrates. Monitoring: periodic liver function tests recommended. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Atorvastatin can interact with a variety of medicines; clinicians should assess the risk before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase atorvastatin levels. - Gemfibrozil: increases risk of myopathy and rhabdomyolysis. - Cyclosporine: raises plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids (aluminum, magnesium): may reduce absorption; separate dosing by at least 2 h. - Warfarin: may enhance anticoagulant effect; monitor INR. - Niacin: combined therapy can increase risk of liver enzyme elevation.